alexa A New Mutation Identified in an Imatinib and Nilotinib Resistant Chronic Myeloid Leukemia Patient | OMICS International | Abstract
ISSN: 2167-7700

Chemotherapy: Open Access
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

A New Mutation Identified in an Imatinib and Nilotinib Resistant Chronic Myeloid Leukemia Patient

Hui Cheng, ChongMei Huang, HuiYing Qiu, WeiPing Zhang, Li Chen, XianMin Song, JianMin Yang and JianMin Wang*

Institute of Hematology, Changhai Hospital, Second Military Medical University, Shanghai 200433, P.R. China

*Corresponding Author:
Jianmin Wang
Department of Hematology
Changhai Hospital, Shanghai 200433, P.R. China
Tel: 86-21-3116-1293
E-mail: [email protected]

Received date: November 23, 2015 Accepted date: February 24, 2016 Published date: February 27, 2016

Citation: Cheng H, Huang C, Qiu H, Zhang W, Chen L, et al. (2016) A New Mutation Identified in an Imatinib and Nilotinib Resistant Chronic Myeloid Leukemia Patient. Chemo Open Access 5:193. doi:10.4172/2167-7700.1000193

Copyright: © 2016 Cheng H, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Chronic myeloid leukemia (CML) is a heterogeneous disease induced by BCR-ABL oncogene. Since the emergence of Tyrosine kinase inhibitors(TKIs), treatment of CML has been drastically changed. However, resistance and intolerance of TKIs have frequently been reported, especially in advanced-stage patients. The most critical reason for TKIs resistance is point mutations within the ABL1 kinase domain that interfere the binding of ABL1 with TKIs. The types and frequencies of mutations have been reported in different population. In this study, we identified a new mutation A2387G (N796S) within the BCR domain (exon 10) via next generation exon sequencing in an imatinib and nilotinib resistant CML patient.

Keywords

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version